Pharma & Bio
Lifestyle
Noh Hae-sung, CTO of GENINUS Inc.: “Patient Data Determines Success or Failure in AI-Driven New Drug Development… Spatial Omics Is the Answer”
“Going forward, success or failure in AI-driven new drug development will hinge not on having better AI models, but on who secures better data.”Noh Hae-sung GENINUS Inc.(389030), Head of Research and …
Technology
Lee Soo-jin, CEO of Aptabio Therapeutics Inc.: “We’re Targeting the Post-Lenvima Era… APX-343A as a Combination Therapy with Keytruda”
“We are not trying to compete with existing immunotherapy drugs. APX-343A’s role is to make existing immunotherapy drugs more effective.”As competition in the development of immuno-oncology drugs ente…
Technology
InBody Rallies on GLP-1 Buzz, Cellid Sinks [K-Bio Pulse]
Shares of South Korean biotech companies moved sharply in different directions on Monday as company-specific developments drove investor sentiment. InBody extended its rally and climbed to a fresh 52-…
Technology
GLP-1 Tailwinds: InBody Co., Ltd. and Synergy Expected for ARIBIOLAB… Cellid Co., Ltd. Faces ‘Clinical Setback’ [Bio Spotlight]
On the 30th, while stock prices of domestic pharmaceutical, biotech, and healthcare companies were generally sluggish, a few companies stood out with strong performance. InBody Co., Ltd.(041830)contin…
Lifestyle
Ensol Bio Makes Another Attempt at Relisting on KOSDAQ... ‘Green Light’ as It Demonstrates Profitability and Technological Capabilities
Ensol Biosciences (hereinafter “Ensol Bio”), a company specializing in the development of innovative new drugs, is moving full steam ahead with its transfer listing to KOSDAQ. Unlike its previous atte…
Lifestyle
New Approach to Treating Fishy Odor Syndrome… Yoon Sang-seon, CEO of Biomi: “Directly Breaking Down TMA in the Gut”
“Telling patients with fishy odor syndrome not to eat eggs or meat is not a realistic treatment. People have to eat to survive.”These were the first words heard during an exclusive interview conducted…
Lifestyle
Why ECM Skinbooster Is Maintaining a ‘Two-Track’ Approach to Distribution and Sales
Amid an explosive surge in demand for extracellular matrix (ECM)-based products in the skin booster market, HANS BIOMED CORPORATION(042520)and L&C BIO(290650)—which currently dominate the domestic mar…
Lifestyle
[Bio USA] Jeong In-ki, CEO of GID Partners and “Key Player in the Hanmi Big Deal”: “Big Pharma Was the First to Discover a Cell Therapy for Parkinson’s Disease”
“To be honest, I was skeptical at first. I wondered if a treatment that involves directly implanting cells into the brain of each individual patient was even realistically possible. But after reviewin…
Technology
Lee Soo-jin, CEO of Aptabio Therapeutics Inc.: “Concerns About the ADC ‘Red Ocean’… Big Pharma Companies Are Taking Notice of APTA-16”
“While most of the meetings at Bio USA are related to APX-115, there is also considerable interest in APTA-16, which is still in the preclinical stage. This is because global pharmaceutical companies …
Lifestyle
Vaxcell-Bio Therapeutics Set to Benefit Most from Revisions to the Advanced Biotechnology Act… O-Rim Rises on Expectations of a 'Big Deal' in China [Bio Spotlight]
On the 29th, the domestic pharmaceutical and life sciences sectors surged in tandem. The pharmaceutical sector index rose 9.52% compared to the previous trading day, with 143 out of 160 listed stocks …